FDA approves Xerava to treat complex intracranal infections in adults over 18 years of age

recently, the U.SFood andDrug(
FDA()) has approved Xerava to treat complex intracranic infections (intried intra-abdominals, cIAIs) in adults over the age of 18Eravacyclin
Eravacycline is an injectable, all-
synthetic(fluoride tetracycline antimicrobials)For clinically common gramobacteria positive, negative oxygen demand and compound anaerobic bacteria, most anaerobic bacteria as well as cephalosporins, large cyclolates, beta-lactamic/beta-lactamase inhibitors have strong in vitro antibacterial activityin clinicaltrials (in which eravacycline is well tolerated in patients with cIAI, has a high clinical cure rate, and is statistically inferior to two widely used contrastagents (Etapenan and Meropinan)complex intra-abdominal infection is the second most common infection in the intensive care unit (ICU) and the second leading cause of infection-related mortality in the ICUAs the crisis of antibiotic resistance worsens, treatment options for these polymesaid infections are limited after surgery or dermal drainage, and pathogenic pathogens can be multiple drug-resistantThere are limitations to the current empirical treatment of cIAI and new treatments are needederavacycline has a wide range of antibacterial activity and clinical profiles to address this unmet medical need safety
Eravacycline has shown good safety characteristics in clinical trials without the need to adjust the dose for patients with kidney damage The drug can also be safely used in patients with penicillin allergies This new treatment may be of great benefit to patients with complex celiac infections